Φορτώνει......
Anti-leukemic effect of CDK9 inhibition in T-cell prolymphocytic leukemia
T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy characterized by chemotherapy resistance and a median survival of less than 2 years. Here, we investigated the pharmacological effects of the novel highly specific cyclin-dependent kinase 9 (CDK9) inhibitor LDC526 and its clinically...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Ther Adv Hematol |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
SAGE Publications
2020
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7570784/ https://ncbi.nlm.nih.gov/pubmed/33117517 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720933761 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|